VCYT - Veracyte, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Veracyte, Inc.

6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650-243-6300
http://www.veracyte.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees270

Key Executives

NameTitlePayExercisedYear Born
Ms. Bonnie H. AndersonCo-Founder, Chairman & CEO1.07MN/A1958
Mr. Keith S. Kennedy CFA, CPACFO, COO & Sec.869.1kN/A1970
Mr. Mark HoPrincipal Accounting OfficerN/AN/A1973
Dr. Giulia C. Kennedy Ph.D.Chief Scientific & Medical OfficerN/AN/A1959
Mr. Ashish KheterpalChief Information OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate Governance

Veracyte, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.